GlaxoSmithKline News and Research

RSS

Cellular program could turn T cells into effective cancer killers

Cancer-fighting immune cells in patients with lung cancer whose tumors do not respond to immunotherapies appear to be running on a different "program" that makes them less effective than immune cells in patients whose cancers respond to these immune treatments, suggests a new study led by researchers at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy.

9 Sep 2021

Coronavirus buildup in the lungs is likely behind high mortality rates

A buildup of coronavirus in the lungs is likely behind the steep mortality rates seen in the pandemic, a new study finds.

31 Aug 2021

Hot spots where covid vaccination lags push experimental antibody treatment

For months, Joelle Ruppert was among the millions of Americans who are covid vaccine holdouts. Her reluctance, she said, was not so much that she opposed the new vaccines but that she never felt "compelled" by the evidence supporting their experimental use.

25 Aug 2021

Pregnant and lactating women did not experience increased reactions after COVID-19 vaccination

A survey of more than 17,000 pregnant and lactating individuals who received the COVID-19 vaccine showed that the individuals did not experience symptoms any more severe than their non-pregnant counterparts.

17 Aug 2021

National academies’ report took pharma-friendly stance after millions in gifts from drugmakers

To several U.S. senators, it looked wasteful, even outrageous. Every year, taxpayers pay for at least $750 million worth of expensive pharmaceuticals that are simply thrown away. Companies ship many of the drugs in "Costco"-size vials, one lawmaker said, that once opened usually cannot be resealed or saved for other patients. Yet pharma gets paid for every drop.

12 Aug 2021

Youth-onset type 2 diabetes is more aggressive and difficult to control, study shows

People with type 2 diabetes diagnosed during youth have a high risk of developing complications at early ages and have a greater chance of multiple complications within 15 years after diagnosis.

28 Jul 2021

Dual-antibody combination therapies effective against SARS-CoV-2 variants in animal study

COVID-19 therapies made from antibodies often are given to patients who are at high risk of severe illness and hospitalization. However, there have been nagging questions about whether such antibody therapies retain their effectiveness as worrisome new virus variants arise.

21 Jun 2021

New strategy for developing universal flu vaccine

A new study from the University of Chicago and Scripps Research Institute shows that during the last great pandemic--2009's H1N1 influenza pandemic--people developed strong, effective immune responses to stable, conserved parts of the virus.

4 Jun 2021

FDA approves investigational monoclonal antibody therapy sotrovimab for COVID-19

The U.S. Food and Drug Administration (FDA) has given the green light on the investigational monoclonal antibody therapy, sotrovimab, as a coronavirus disease (COVID-19) treatment.

1 Jun 2021

Infrared thermal imaging camera can help monitor the progression of lymphatic filariasis

A paper published in the Journal of Clinical Medicine presents the results from a study which examined the use of an infrared thermal imaging camera as a novel non-invasive point-of-care tool for lymphatic filariasis lower-limb lymphoedema.

26 May 2021

Study reveals genes that cause loss of lung function in active smokers

Chronic Obstructive Pulmonary Disease (COPD) is a disease caused by cigarette smoking that reduces lung function and causes difficulty breathing. It is the third leading cause of death worldwide. Current treatments for COPD only affect symptoms, not progression. Identifying who is going to get COPD before they get it is key to figuring out how to intercept the disease at an early stage.

12 May 2021

FDA approves immunotherapy for treating patients with dMMR endometrial cancer

Today, the U.S. Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR (which contain abnormalities that affect the proper repair of DNA inside the cell), as determined by an FDA-approved test.

22 Apr 2021

Parkinson’s UK, University of Sheffield to develop new Parkinson’s drug

Parkinson's UK, the largest charitable funder of Parkinson's research in Europe, is investing up to £1.2 million into a pioneering one-year project in partnership with the University of Sheffield.

9 Mar 2021

Biden’s criticism of Trump team’s vaccine contracts is a stretch

During a March 2 news conference on the covid-19 pandemic, President Joe Biden claimed that former President Donald Trump's administration did not ensure there would be enough vaccines for the American public.

8 Mar 2021

ACTIV-3 clinical trial evaluating investigational COVID-19 therapies closes enrollment in two sub-studies

The ACTIV-3 clinical trial, which is evaluating the safety and efficacy of investigational therapeutics for COVID-19 in hospitalized patients, has closed enrollment in two sub-studies: one examining the investigational monoclonal antibody therapy VIR-7831, and another evaluating the investigational combination monoclonal antibody therapy containing BRII-196 and BRII-198.

5 Mar 2021

Experimental safety switch reduces severity of CAR-T immunotherapy-related side effects

UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur.

4 Mar 2021

GW team to play a role in Sanofi COVID-19 vaccine clinical trial

The George Washington University announced today its participation in a Sanofi COVID-19 vaccine clinical trial. GW was selected as one of approximately 25 sites in the United States to launch a phase 2 study for its adjuvanted recombinant protein-based COVID-19 vaccine candidate.

24 Feb 2021

Targeted drug combined with immunotherapy prolongs survival in patients with advanced kidney cancer

Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.

13 Feb 2021

Wistar researchers discover new enzymatic function of the Epstein-Barr Virus protein

Researchers at The Wistar Institute have discovered a new enzymatic function of the Epstein-Barr Virus (EBV) protein EBNA1, a critical factor in EBV's ability to transform human cells and cause cancer.

27 Jan 2021

Experts focus on identifying key research priorities related to AF screening

Atrial fibrillation (AF) is associated with a higher risk of complications including ischemic stroke, cognitive decline, heart failure, myocardial infarction and death. AF frequently is undetected until complications such as stroke or heart failure occur.

26 Jan 2021